ImmunoBrain Checkpoint adds Dr. James Mackay to its Board of Directors

– ISRAEL, Ness Ziona –  ImmunoBrain Checkpoint Inc., a clinical-stage biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced the appointment of Dr. James Mackay (Ph.D.) to its Board of Directors, bringing decades of biopharma leadership experience to the Board of Directors.

“Dr. Mackay’s intimate knowledge of global development and commercialization will be critical for the growth and expansion of ImmunoBrain Checkpoint as we continue to build our global footprint in clinical trials of IBC-Ab002. His profound understanding of the biopharma landscape, specifically in the development of therapeutics that focus on immunology, makes Dr. Mackay an exceptional addition to our leadership team,” said Co-founder and Executive Chairman, Nathan Hevrony.

About Dr. James M. Mackay

Dr. Mackay has more than 25 years of experience in the pharmaceutical and biotech industry. He has leveraged his expertise in the development and commercialization of therapeutic compounds across multiple indications to bring 6 drug products to the market. Most recently, Dr. Mackay served as Founder, President, and CEO at Aristea Therapeutics where he led a team of scientists and business professionals in developing novel immunology-focused therapeutics for the treatment of autoimmune and inflammatory diseases. Before founding and leading Aristea, Dr. Mackay led Ardea Biosciences following its $1.26 billion acquisition by AstraZeneca. Earlier, Dr. Mackay held a wide range of senior leadership roles at AstraZeneca. He currently holds board seats with several biotechnology companies and non-profits within the life sciences industry.

“ImmunoBrain Checkpoint is at the forefront of innovation in the two fields of immunology and neurodegenerative disease,” said Dr. James Mackay. “Its novel approach to treating some of the most complex neurological conditions through the peripheral immune system is backed by rigorous science. I look forward to applying my previous experience in immunological drug development as a member of the Board of Directors for a company that has the potential to be truly disruptive in the neurodegenerative disease space.”

Dr. Mackay earned his BS in Genetics and Ph.D. in Medical Genetics from Aberdeen University, Scotland.

About ImmunoBrain Checkpoint

ImmunoBrain Checkpoint is a biopharmaceutical company developing novel immune therapies to combat neurodegenerative diseases. Established in 2015, IBC builds on over 20 years of research by Professor Michal Schwartz’s team at the Weizmann Institute of Science, which pioneered the concept that the brain relies on the immune system for maintenance and repair, with this communication compromised in aging and Alzheimer’s disease. This research led to the development of IBC-Ab002, an antibody that targets an inhibitory immune checkpoint to rewire brain/immune communication and protect the brain from functional loss. The company is currently investigating IBC-Ab002 in the IBC-01-01 clinical trial for Alzheimer’s disease [NCT05551741], which is supported in part by grants from the National Institute on Aging and the Alzheimer’s Association.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.